Open-label placebo treatment to reduce appetite/overeating in obese children: an app-assisted approach

Open-label placebo treatment to reduce appetite/overeating in obese children: an app-assisted approach - OLP treatment for obese children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00029251

Enrollment

Registered

2022-06-07

Start date

2022-09-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity E66.04

Interventions

Group 1: 4 weeks with placebo treatment Group 2: 4 weeks without placebo treatment

Eligibility

Sex/Gender

All

Age

8 Years to 12 Years

Inclusion criteria

Inclusion criteria: BMI > 90th percentile

Exclusion criteria

Exclusion criteria: • Medication (e.g., antidepressants, appetite suppressants) • Somatic diseases (e.g., neurological disorders, digestive problems) • Mental disorders (e.g., ADHD, eating disorders) • Puberty (menstruation, pubic hair, voice fluctuation, breast-growth, acne)

Design outcomes

Primary

Measure	Time frame
Comparison of appetite reduction between the 4 weeks with vs. without OLP (Open-Label-Placebo)	—

Secondary

Measure	Time frame
Comparison of body weight at the end of 4 weeks with vs. without OLP (Open-Label-Placebo) treatment	—

Countries

Austria

Contacts

Public ContactAnne Schienle

Universität Graz

anne.schienle@uni-graz.at+43 316 380-5086

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026